Pimecrolimus for the treatment of inflammatory skin disease

Bibliography

• LEUNG DYM, EICHENFIELD LF,BOGUNIEWICZ M: Atopic dermatitis (atopic eczema). In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):1180–1194.
   Google Scholar
• •State of the art review of AD.
   Google Scholar
• LEUNG DYM: Atopic dermatitis: new insights and opportunities for therapeutic intervention. I Allergy Clin. Immunol (2000) 105:860–876.
   PubMed Web of Science ®Google Scholar
• BACH JF: The effect of infections on susceptibility to autoimmune and allergic disease. N Engl. J. Med. (2002) 347:911–920.
   PubMed Web of Science ®Google Scholar
• EICHENFIELD LF, HANIFIN JM, BECK LA et al.: Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics (2003) 111:608–616.
   PubMed Web of Science ®Google Scholar
• ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. (2002) 347:1151–1160.
   PubMed Web of Science ®Google Scholar
• LEUNG DY, HANIFIN JM, CHARLESWORTH EN et al.: Disease management of atopic dermatitis: a practice parameter. Jount Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann. Allergy Astma Immunol (1997) 79:197–211.
   Google Scholar
• BOGUNEIWICZ M, LEUNG DYM: New concepts in atopic dermatitis. Compc Titer. (1996) 22:144–151.
   PubMedGoogle Scholar
• CHARMAN CR, MORRIS AD, WILLIAMS HC: Topical corticosteroid phobia in patients with atopic eczema. Br. J. Dermatol (2000) 142:931–936.
   PubMed Web of Science ®Google Scholar
• KRUTMANN J, MORITA A: Therapeutic photomedicine: Phototherapy. In: Fitzpatrick's Dermatology in GeneralMedicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):2469–2477.
   Google Scholar
• HONIGSMANN H, SZEIMIES KNOBLER R et al.: Photochemotherapy and photodynamic therapy. In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):2477–2493.
   Google Scholar
• ATAKAN N, ERDEM C: The efficacy, tolerability and safety of a new oral formulation of Sandimmun — Sandimmun Neoral in severe refractory atopic dermatitis. J. Ear: Acad. Dermatol Venereol (1998) 11:240–246.
   PubMed Web of Science ®Google Scholar
• RUZICKA T, BIEBER T, SCHOPF E et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl. J. Med. (1997) 337:816–821.
   PubMed Web of Science ®Google Scholar
• REITAMO S, WOLLENBERG A, SCHOPF E et al.: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.Arch. Dermatol (2000) 136:999–1006.
   Google Scholar
• PALLER A, EICHENFIELD LF, LEUNG DY et al.: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J. Am. Acad. Dermatol (2001) 44:547–557.
   Web of Science ®Google Scholar
• CHRISTOPHERS E, MROWIETZ U. Psoriasis. In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):407–427.
   Google Scholar
• •State of the art review of psoriasis.
   Google Scholar
• ALTMEYER P, MATTHES U, PAWLAK F et al.: Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients.J. Am. Acad. Dermatol (1994) 30:997–981.
   Google Scholar
• KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. Am. Acad. Dermatol (2002) 46:1–23.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, KRUEGER JG:Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. I Med. (2001) 345:248–255.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, KRUEGER JG, WITTKOWSKI K et al.: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol (2002) 38:591–600.
   Google Scholar
• CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial.Lancet (2001) 357:1842–1847.
   Google Scholar
• MEASE PJ, GOFFE BS, METZ J et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, WALTERS TB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high affinity interleukin 2 receptor) on T cells by administration of humanized anti-TAC antibody to patients with psoriasis.Am. Acad. Dermatol (2000) 43:448–458.
   Google Scholar
• ARAI T, KOYOMA Y, SUENAGA T et al.: Ascomycin, an antifungal antibiotic. Antibior SerA (1962) 15:231–234.
   PubMed Web of Science ®Google Scholar
• STUETZ A, GRASSBERGER M, MEINGASSNER JG:Entstehungsgeschichte und präklinisches Profil von Pimecrolimus. Hautarzt (2003) 54:405–412.
   PubMedGoogle Scholar
• STUETZ A, GRASSBERGER M, BAUMANN K et al.: Immunophilins as drug targets, In: Perspectives in Medicinal Chemistry Testa B, Kyburz E, Fuhrer W et al.: (Eds), Verlag Helvetica Chimica Acta, Basel, Weinheim, Verlag Chemie, (1993):427–443.
   Google Scholar
• GRASSBERGER, M, RAPPERSBERGERK, MEINGASSNERJG et al.: Ascomycins, In: Psoriasis Roenigk HH, Maibach H (Eds), Marcel Dekker, New York, NY, USA (1998):769–779.
   Google Scholar
• PAUL C, GRAEBER M, STUETZ A: Ascomycins. Promising agents for the treatment of inflammatory skin diseases. Expert Opin. Investig. Drugs (2000) 9:69–77.
   PubMed Web of Science ®Google Scholar
• ••A seminal review pimecrolimus.
   Google Scholar
• MEINGASSNER JG, STUETZ A: Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int. Arch. Allergy Immunol (1992) 99:486–489.
   PubMed Web of Science ®Google Scholar
• MEINGASSNER JG, STUETZ A: Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases. I Invest. Dermatol (1992) 98:851–855.
   PubMed Web of Science ®Google Scholar
• RAPPERSBERGER K,MEINGASSNER JG, FIALLA R et al: Clearing of psoriasis by a novel immunosuppressive macrolide.Invest. Dermatol (1996) 106:701–710.
   PubMed Web of Science ®Google Scholar
• •A pivotal study demonstrating clinical effectiveness of an ascomycin in psoriasis.
   Google Scholar
• GRASSBERGER M, BAUMRUKER T, ENZ A et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br: J. Dermatol (1999) 141:264–273.
   Google Scholar
• MEINGASSNER JG, GRASSBERGER M, FAHRNGRUBER H et al: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br. I Dermatol (1997) 137:568–576.
   PubMed Web of Science ®Google Scholar
• STUETZ A, GRASSBERGER M, MEINGASSNER JG: Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin. Cutan. Med. Surg. (2001) 20:233–241.
   PubMed Web of Science ®Google Scholar
• ••An important review of the predinicalpharmacology of pimecrolimus.
   Google Scholar
• VAN LEENT EJM, GRABER M, THURSTON M et al.: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol (1998) 134:805–809.
   PubMedGoogle Scholar
• •A pivotal study demonstrating the effectiveness of topical pimecrolimus in AD.
   Google Scholar
• HARPER J, GREEN A, SCOTT G et al.: First experience of topical SDZ ASM 981 in children with atopic dermatitis.\Br. Dermatol (2001) 144:781–787.
   Google Scholar
• LUGER T, VAN LEENT EJM, GRAEBER M et al: SDZ-ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. I Dermatol (2001) 144:788–794.
   PubMed Web of Science ®Google Scholar
• HO V, GUPTA A, KAUFMANN R et al.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. Pediatr. (2003) 142:155–162.
   Web of Science ®Google Scholar
• ALLEN BR, LAKHANPAUL M, MORRIS A et al.: Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch. Dis. Child. (2003) 88(11):969–973.
   PubMed Web of Science ®Google Scholar
• WAHN U, BOS JD, GOODFIELD M et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.Pediatrics (2002) 110:e2.
   PubMed Web of Science ®Google Scholar
• MEURER M, FOLSTER-HOLST R, WOZEL G et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (2002) 205:271–277.
   PubMed Web of Science ®Google Scholar
• KAPP A, PAPP K, BINGHAM A et al: Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. I Allergy Clin. Immunol (2002) 110:277–284.
   PubMed Web of Science ®Google Scholar
• LUGER T, VAN LEENT EJM, GRAEBER M et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. Dermatol (2001) 144:788–794.
   PubMed Web of Science ®Google Scholar
• EICHENFIELD LF, LUCKY AW, BOGUNEIWICZ M et al: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of atopic dermatitis in children and adolescents. Am. Acad. Dermatol (2002) 46:495–504.
   PubMed Web of Science ®Google Scholar
• QUEILLE-ROUSSEL C, PAUL C, DUTEIL L et al: The new topical ascomycin derivative SDZ ASM 981 doesnot induce skin atrophy when applied to normal skin for four weeks: a randomized, double-blind controlled study.Br. .1. Dermatol (2001) 144:507–513.
   PubMed Web of Science ®Google Scholar
• VAN LEENT EJM, EBELIN ME, BURTIN P et al.: Low systemic exposure after repeated topical application of pimecrolimus (Elidel9, SDZ ASM 981) in patients with atopic dermatitis. Dermatology (2002) 204:63–68.
   Web of Science ®Google Scholar
• •An important study showing low blood levels of pimecrolimus after topical application.
   Google Scholar
• ALLEN BR, LAKHANPAUL M, MORRIS et al: Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch. Dis. Child (2003) 88:969–973.
   PubMed Web of Science ®Google Scholar
• ALLEN R, DAVIES T, BOS JD et al.: SDZ ASM 981: Pharmacokinetics in adults and children. I Eur: Acad. Dermatol Venereol (2000) 14\(Suppl. 1):91–92 (Abstract).
   Google Scholar
• VAN LEENT EJM, DEVRIES JC, EBELIN ME et al.: Low blood concentrations of pimecrolimus (SDZ ASM 981) in adult atopic dermatitis patients treated topically for up to 1 year. 60-h Annual Meeting of the American Academy of Dermatology New Orleans, (2002) (Abstract).
   Google Scholar
• LAKHANPAUL M, DAVIES T, ALLEN B et al.: Pimecrolimus (SDZ ASM 981) cream 1%: minimal systemic absorption in infants with atopic dermatitis during long-term treatment. Ann. Dermatol Venereol (2002) 129:1S415 (Abstract).
   Google Scholar
• DAVIES T, ALLEN R, CARDNO M et al.: Low systemic SDZ ASM 981 concentrations in 3 months-2 year old children with extensive atopic dermatitis treated with 1% cream. Br. J. Dennatol (2000) 143:75-76 (Abstract).
   Google Scholar
• EICHENFIELD LF: Safety,Apharmacokinetics, tolerability, and efficacy of topical SDZ ASM 981 (pimecrolimus) and FK506 (tacrolimus) in pediatric atopic dermatitis: a comparison of clinical studies. Intemnational Symposium on Atopic Dermatitis, Portland, Oregon September 6–9 (2001) (Abstract).
   Google Scholar
• GRAHAM-BROWN RAC, GRASSBERGER M: Pimecrolimus: a review of pre-clinical and clinical data. Int. J. Clin. Pract. (2003) 57:319–327.
   PubMed Web of Science ®Google Scholar
• •A thorough review of pimecrolimus.
   Google Scholar
• RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. Invest. Dermatol (2002) 119:876–887.
   PubMed Web of Science ®Google Scholar
• ••A seminal study showing effectiveness and(short-term) safety of oral pimecrolimus in psoriasis. This study also includes pharmacokinetics and is the first study of its kind to demonstrate the pharmacogenomics of a drug in human disease.
   Google Scholar
• HANIFIN J, FLEMING C, KORMAN N et al.: Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose-response effect. J. Invest. Dermatol (2003) 121:1240 (Abstract).
   Google Scholar
• WINISKI A, WANG S,SCHWENDINGER B et al.: Effect of pimecrolimus, tacrolimus, cyclosporin A, betamethasone 17-valerate, dexamethasone and hydrocortisone on cytokine production and T-cell proliferation induced in human peripheral blood mononuclear cells (conference abstract). Invest. Dermatol (2003) 121\(No. 1): Abstract 1225.
   Google Scholar
• KALTHOFF FS, CHUNG J, STUETZ A: Pimecrolimus inhibits upregulation of 0X40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.Gin. Exp. Immunol (2002) 130:85–92.
   PubMed Web of Science ®Google Scholar
• HULTSCH T, MOLLER KD, MEINGASSNER JG et al.: Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesiszed cytokines in RBL 2H3 mast cels in an immunophilin-dependent manner. Arch. Dermatol Res. (1998) 290:501–507.
   PubMed Web of Science ®Google Scholar
• ZUBERBIER T, CHONG SU, GRUNOW K et al.: The ascomycinmacrolactam pimecrolimusSDZASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. I Allergy Clin. Immunol (2001) 108:275–280.
   PubMed Web of Science ®Google Scholar
• KALTHOFF FS, CHUNG J, MUSSER P et al.: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin. Exp. Immunol (2003) 133:350–359.
   PubMed Web of Science ®Google Scholar
• MEINGASSNER JG, KOWALSKY E, SCHWENDINGER H et al.: Pimecrolimus does not affect Langerhanscells in murine epidermis.Br. J. Dermatol (2003) 149:853–857.
   PubMed Web of Science ®Google Scholar
• HOETZENEGGER W,MEINGASSNERJG, ECKER R et al: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J. Invest. Dermatol (2003) (In Press).
   Google Scholar
• MEINGASSNERJG, FAHRNGRUBER H, BAVANDI A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. I Invest. Dermatol(2003) 121:77–80.
   PubMed Web of Science ®Google Scholar
• MEINGASSNERJG, FAHRNGRUBER H, SCHWEITZER A et al.: Pimecrolimus inhibits allergic contact dermatitis in rodents without affecting draining lymph nodes, different to tacrolimus. I Invest. Dermatol (2002) 119:343 (Conference Abstract).
   Google Scholar
• NECKERMANN G, BAVANDI A, MEINGASSNER JG: Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br. I Dermatol (2000) 142:669–679.
   PubMed Web of Science ®Google Scholar
• MAHL A, ROMAN D, COURT M, VIT P et al.: Pimecrolimus shows in contrast to tacrolimus and cyclosporine only marginal effects on immunization at oral administration in a rat model. I. Invest. Dermatol (2003) 121(1) (Abstract 1226).
   Google Scholar
• BILLICH A, ASCHAUER H, ASZODY A et al.: Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus.Int. I Pharmaceutics (2004) 269:29–35.
   PubMed Web of Science ®Google Scholar
• KOIVUKANAGAS V, KARVONEN J, RISTELI J et al.: Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo.Br. I Dermatol (1995) 132:66–68.
   Google Scholar
• HAAPASAARI KM, RISTELI J, KARVONEN J et al: Effect of hydrocortisone methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol (1997) 135:1104–1110.
   Google Scholar
• CHEILL R, TOFTE S, MACNAUL R et al: SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. I Eur. Acad. Dermatol Venereol (2000) 14\(Suppl. 1):128 (Abstract).
   Google Scholar
• QUEILLE-ROUSSEL C, GRAEBER M,THURSTON M et al.: SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Berm. (2000) 42:349–350.
   Google Scholar
• AMROL D, KEITEL D, HAGAMAN D, MURRAY J: Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann. Allergy Asthma Immunol (2003) 91:563–566.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, BRAEUTIGAM M, GRAEBER M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol (1998) 139:992–996.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, WUSTLICH S, HOEXTER G et al.: Pimecrolimus SDZ ASM 981) ointment is effective in psoriasis without occlusion (conference abstract) J. Ear: Acad. Dermatol Venereol (2001) 15\(Suppl. 2):244.
   Google Scholar
• BROWNELL I, QUAN LT, HSU S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online (2003) 9:13.
   Google Scholar
• GRIFFITHS C, DUBERTRET L, GOTTLIEB A: Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect..1 Invest. Dermatol (2003) 121:0301 (Abstract).
   Google Scholar
• LUCKY A, MARSHALL K, BUSH C et al:SDZ ASM 981 cream 1% is effective and safe in children and adolescents with atopic dermatitis. Clin. Exp. Dermatol (2001) 26:214 (Abstract).
   Google Scholar
• MEURER M, BRAUTIGAM M: Pimecrolimus (SDZ ASM 981) cream reduces the need for corticosteroids in the long-term management of atopic dermatitis in adults (Abstract). Presented in the 60-h Annual Meeting of the American Academy of Dermatology New Orleas, LA, USA (2002) Poster no. 108.
   Google Scholar
• WAHN U, MOLLOY S, GRAEBER M et al: SDZ ASM 981 cream 1%: a new approach to long-term management of atopic dermatitis.' Invest. Dermatol (2001) 117(2):533 (Abstract).
   Google Scholar
• WHALLEY D, MCKENNA S, HUELS J et al.: The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of pediatric atopic dermatitis: results of two 6-week randomized double-blind vehicle-controlled clinical trials in the US (abstract). J. Eur: Acad. Dermatol Venereol (2001) 15 (Suppl. 2):5112.
   Google Scholar
• BOGUNIEWICZ M, EICHENFIELD L, HONIG P et al.: Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is safe in thelong-term management of atopic dermatitis. Eur. Acad. Dermatol Venereol (2001) 15 (Suppl. 2) :S110 (Abstract).
   Google Scholar
• HANIFIN J. HO V, KAUFMANN R, KAPP A et al.: Pimecrolimus (SDZ ASM 981) cream: good tolerability in paediatric patients. Ann. Dermatol Venereol (2002) 129:1S411 (Abstract).
   Google Scholar
• WOLFF K, CARO I, MURRELL D et al:Safety profile of oral pimecrolimus in atopic eczema and psoriasis: a pooled analysis from two dose-finding studies. I. Invest. Dermatol (2003) 121:1245 (Abstract).
   Google Scholar